All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Assessment of Anti-proliferative Effect of Extract Fractions of Euphorbia neriifolia Leaves in Human Prostate Adenocarcinoma DU-145 Cells

Author(s): P. Y. MALI* AND S. GOYAL
Department of Pharmacology, B. R. Nahata College of Pharmacy, Mandsaur University, Mandsaur, Madhya Pradesh 458001, India

Correspondence Address:
Department of Pharmacology, B. R. Nahata College of Pharmacy, Mandsaur University, Mandsaur, Madhya Pradesh 458001, India, E-Mail: [email protected]


Euphorbia neriifolia Linn. Sp. Pl. (451.1753) belonging to family Euphorbiaceae has several ethnomedicinal uses. To authenticate these uses scientifically, we have assessed anti-proliferative effect of extract fractions of Euphorbia neriifolia leaves in human prostate adenocarcinoma DU-145 cells by 3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyl tetrazolium bromide cell proliferation assay. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide cell proliferation assay was used for assessment anti-proliferative effect of extract fractions of Euphorbia neriifolia leaves in human prostate adenocarcinoma DU-145 and normal (Vero) cells. The cells were treated with series of concentrations of extract fractions (4.12-1000 μg/ml) for 48 h. Doxorubicin was considered as standard anti-cancer drug. In order to inhibition concentration and Selectivity Index results, extract fractions have been classified into 05 categories as described by Prayog et al. No extract fraction (EN1 to EN6) of Euphorbia neriifolia leaves was found in first 02 categories at the tested concentrations. Only doxorubicin standard drug sample was found in second category. It can be concluded that no other cells studies were documented yet on isolates and extract fractions of Euphorbia neriifolia by in vitro methods except murine B16F10 melanoma cells. Therefore, there is a need to carry forward these studies at higher concentrations of extract fractions (EN1 to EN6) in same and other adenocarcinoma cells. It can also be study by using other in vivo allograft and xenograft experimental models to confirm anti-proliferative or anti-cancer effects of these extract fractions.

Full-Text | PDF

 
 
List of Supporting Conferences